Published in Cancer Med on July 08, 2015
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors | NCT01928459
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer | NCT01548144
Erlotinib and Temsirolimus for Solid Tumors | NCT00770263
Functional variants of human papillomavirus type 16 demonstrate host genome integration and transcriptional alterations corresponding to their unique cancer epidemiology. BMC Genomics (2016) 1.38
MicroRNA-125a-5p modulates human cervical carcinoma proliferation and migration by targeting ABL2. Drug Des Devel Ther (2015) 0.76
The importance of regulatory ubiquitination in cancer and metastasis. Cell Cycle (2017) 0.75
Somatic Variations in Cervical Cancers in Indian Patients. PLoS One (2016) 0.75
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. Int J Mol Sci (2017) 0.75
The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
Global cancer statistics. CA Cancer J Clin (2011) 185.92
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
dbSNP: the NCBI database of genetic variation. Nucleic Acids Res (2001) 76.97
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res (2003) 52.26
Sequencing technologies - the next generation. Nat Rev Genet (2009) 40.57
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Cancer genome landscapes. Science (2013) 25.33
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
International network of cancer genome projects. Nature (2010) 20.35
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res (2012) 15.90
InterPro in 2011: new developments in the family and domain prediction database. Nucleic Acids Res (2011) 13.45
Genetic heterogeneity in human disease. Cell (2010) 10.67
COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res (2009) 9.59
From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics (2013) 8.79
FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer (2008) 7.93
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell (2002) 5.64
Papillomaviruses in the causation of human cancers - a brief historical account. Virology (2009) 5.46
The cancer biomarker problem. Nature (2008) 4.64
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
Disease-targeted sequencing: a cornerstone in the clinic. Nat Rev Genet (2013) 3.30
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med (2014) 3.18
Landscape of genomic alterations in cervical carcinomas. Nature (2013) 2.61
LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res (2012) 2.46
Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res (2005) 2.16
Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat (2012) 1.77
Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet (2014) 1.67
Comparison of somatic mutation calling methods in amplicon and whole exome sequence data. BMC Genomics (2014) 1.53
Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A (2003) 1.42
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol (2013) 1.39
Two classes of BRC repeats in BRCA2 promote RAD51 nucleoprotein filament function by distinct mechanisms. Proc Natl Acad Sci U S A (2011) 1.28
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol (2012) 1.27
The role of TP53 in Cervical carcinogenesis. Hum Mutat (2003) 1.23
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health (2008) 1.16
Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. Gynecol Oncol (2007) 1.02
Met activation and receptor dimerization in cancer: a role for the Sema domain. Cell Cycle (2005) 1.00
Recurrent cervical cancer. Curr Treat Options Oncol (2002) 0.97
A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC). BMC Pulm Med (2014) 0.78